Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)”
Phase 2/3 1
- INBRX-106Inhibrx Biosciences, Inc.HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.